A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)

NCT02110225 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa

Interventions

DRUG: rhNGF 60 µg/ml eye drops solution
DRUG: rhNGF 180 µg/ml eye drops solution
DRUG: Placebo

Sponsor

Dompé Farmaceutici S.p.A